Physician profile
Monisha Dutta
NPI 1164634978
$889.11
in general payments reported to CMS, 2019-2025
11 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $111 · 2023: $140 · 2024: $154 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $778.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $210.08 | 2022-2025 | Ongentys, Ingrezza |
| Sk Life Science, INC. | $168.81 | 2022-2025 | |
| Argenx US, INC. | $123.30 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $117.49 | 2023-2025 | Kisunla, Amyvid |
| Novartis Pharmaceuticals Corporation | $95.79 | 2023-2025 | |
| Emd Serono, INC. | $50.49 | 2025 | |
| C2n Diagnostics, LLC | $46.94 | 2025 | Precivityad2 |
| Astrazeneca Pharmaceuticals LP | $24.70 | 2025 | Wainua |
| Alexion Pharmaceuticals, INC. | $21.83 | 2025 | Ultomiris |
| Tg Therapeutics, INC. | $15.45 | 2025 | |
| Pfizer INC. | $14.23 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monisha Dutta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.